Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment by F. Calabrese et al.
Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged
lurasidone treatment
Francesca Calabrese1, Elisa Savino1, Mariusz Papp2, Raffaella Molteni1 and Marco A. Riva1
1Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy; 2Institute of Pharmacology,
Polish Academy of Sciences, Krakow, Poland.
Corresponding author: Prof. Marco A. Riva
Department of Pharmacological and Biomolecular Sciences
University of Milan, Via Balzaretti 9, 20133 Milan, Italy
Phone: +39-02 50318334; Fax: +39-02 50318278
E-mail: M.Riva@unimi.it
Running title: Lurasidone modulate clock gene expression in the CMS model 
1
Abstract 
Disruptions  of  biological  rhythms are known to  be  associated  with  depressive  disorders,  suggesting  that  abnormalities  in  the
molecular clock may contribute to the development of these disorders. These mechanisms have been extensively characterized in
the suprachiasmatic nucleus, but little is know about the role exerted by individual clock genes in brain structures that are important
for depressive disorders. Using the chronic mild stress model we found a significant reduction of BMAL1 and CLOCK protein levels
in the nuclear compartment of the prefrontal cortex of CMS rats, which was paralleled by a down-regulation of the expression of
several target genes, including Pers and Crys but also Reverbβ and Pparα. 
Interestingly,  chronic  treatment  with  the multi  receptor  modulator  lurasidone (3  mg/kg for  5  weeks) was  able  to normalize the
molecular changes induced by CMS exposure in prefrontal cortex, but it was also able to regulate some of these genes within the
hippocampus. 
We believe  that  changes  in  clock  genes  expression  after  CMS exposure may contribute  to  the disturbances  associated with
depressive disorders and that the ability of chronic lurasidone to normalize such alterations may be relevant for its therapeutic
properties in ameliorating functions that are deteriorated in patients with major depression and other stress-related disorders.
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Introduction 
Depressive disorders are characterized by complex and heterogeneous symptoms, including alterations of biological rhythms that
can manifest, for example, with changes in sleep-wake cycle  (1). At the bases of these modifications there is a disruption of the
circadian clock since it has been demonstrated that the intensity of major depressive symptoms in human is correlated with the
misalignment  of  circadian  rhythms  (2).  Furthermore  mutations  in  circadian  genes  are  found  in  depressed  subjects  and  may
contribute to specific symptoms (3). Moreover, considering the importance of cell birth and proliferation in the hippocampus in mood
and in the antidepressant activity, the alterations in neurogenesis observed following chronic circadian disruption (4) confirm that this
process may contribute to the development or exacerbation of depressive disorders. 
While the pacemaker cells controlling most of the circadian rhythms are located in the suprachiasmatic nucleus (SCN), it has been
recently demonstrated that patients with major depressive disorder show profound alterations of hundreds of genes that have a
rhythmic transcriptional activity in regions outside the SCN (5).
At molecular level, the circadian clock involves periodic changes in gene expression achieved by transcription-translation feedback
loops whereby the protein product of transcribed genes auto-regulate their own transcription. In mammals, the circadian clock is
composed of an auto-regulatory transcriptional network with an interlocked feedback loop. Specifically, the core transcriptional circuit
comprises  the transcription  factors BMAL1 and CLOCK that  heterodimerize and activate the transcription of  Period (Per)  and
Cryptochrome (Cry) genes. PER/CRY proteins then repress their own transcription by inhibiting the activity of CLOCK:BMAL1 until
they are degraded to allow a new cycle of transcription to begin (6). In addition, the interlocking feedback loop regulated rhythmic
expression of  Bmal1 through opposing action of  the ROR and REV-ERB families that activate and repress  Bmal1 transcription
respectively and whose expression is controlled by the core loop (6). 
Since depression can be the consequence of  altered and often maladaptive response to stress,  models  in  which animals are
exposed to  different  paradigms of  stress  during  adult  life  are  supposed to  disrupt  normal  homeostasis,  leading  to  pathologic
alterations. Among the wide array of experimental paradigms employed in rodents to investigate the mechanisms that may contribute
to stress-related disease susceptibility, the chronic mild stress (CMS) model is a well-validated paradigm to induce depressive-like
behavior, which is also associated with significant alterations of circadian rhythms (7).
On these bases, in the present study we have used the CMS paradigm to establish possible changes in the expression of the clock
genes in brain regions different from the SCN, such as prefrontal cortex and hippocampus, which play a key role in core symptoms
of major depressive disorders. Furthermore, we have investigated the ability of  the multi-receptor modulator lurasidone to normalize
stress-induced changes of  clock genes expression. Even if  lurasidone was initially introduced as an antipsychotic  drug,  recent
evidence indicate that it also has antidepressant (8, 9) and procognitive activity both in rats and primates (10, 11). 
Moreover, we have recently shown that prolonged treatment with  lurasidone normalizes the behavioral as well as the molecular
changes at synaptic levels due the exposure to CMS (12). 
We analyzed  the  transcriptional  levels  of  genes  involved  in  the  core  (Bmal1,  Clock,  Per1,  Per2,  Cry1 and  Cry2)  and  in  the
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interlocking feedback loop (Rev-Erbα and Rev-Erbβ) in the prefrontal cortex as well as in dorsal and ventral hippocampus. Moreover,
we investigated the mRNA levels of Pparα, Nampt and Bhlhe40 whose expression is regulated by the heterodimer CLOCK:BMAL1.
Finally, we analyzed the protein levels of BMAL1, CLOCK, CRY1 and PER1 in the prefrontal cortex in order to obtain a detailed
picture of the clock machinery under stress conditions as well as in response to pharmacological treatment. 
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Materials and Methods 
General reagents were purchased from Sigma-Aldrich (Milan, Italy) whereas molecular biology reagents were obtained from Life
Technologies (Monza, Italy), PerkinElmer (Milan, Italy), Roche (Monza, Italy), Eurofins MWG-Operon (Ebersberg, Germany) and Bio-
Rad Laboratories S.r.l. (Segrate, Italy). Lurasidone was kindly provided by Sumitomo Dainippon Pharma Co. Ltd (Japan).
Animals 
Adult male Wistar rats (Charles River, Germany) were brought into the laboratory one month before the beginning of the experiment.
The animals were single-housed with food and water freely available, and were maintained on 12-h light/dark cycle with a constant
temperature (22  2oC) and humidity (50 ± 5%) conditions. All procedures used in this study are conformed to the rules and principles
of the 2010/63/EU Directive, were approved by the Local Bioethical Committee at the Institute of Pharmacology, Polish Academy of
Sciences, Krakow, Poland, and adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All
efforts were made to minimize animal suffering and to reduce the number of animals used.
Stress procedure and pharmacological treatment
Animals were divided into two groups: No Stress (control animals) and Stress. Animals were subjected to the stress procedure for 7
weeks. Each week of the stress regime consisted of two periods of food or water deprivation, two periods of 45 degree cage tilt, two
periods of intermittent illumination (lights on and off every 2h), two periods of soiled cage (250 mL water in sawdust bedding), one
period of paired housing, two periods of low intensity stroboscopic illumination (150 flashes/min), and three periods of no stress. All
stressors were 10-14 h of duration and were applied individually and continuously, day and night. Control animals were housed in
separate rooms and had no contact with the stressed animals. 
Based on the results of the final sucrose test carried out the following first 2 weeks of stress (12), both control and stress-reactive
groups were further divided into matched subgroups (n=10) and for the subsequent five weeks they received oral administration (by
gavage) of vehicle (hydrossi-ethil-cellulose, HEC 1%) or lurasidone (3 mg/kg daily). The stress was continued throughout the entire
period of drugs administration. After five weeks, the treatments were terminated and all the animals were killed by decapitation 24h
after (between 11:00 and 14:00) the last drug administration. The hippocampus (dorsal and ventral) and the prefrontal cortex were
rapidly dissected. The dorsal hippocampus corresponds to the plates 25-33 according to the atlas of Paxinos and Watson (Paxinos
and Watson, 1996), whereas the ventral hippocampus corresponds to the plates 34-43. The prefrontal cortex (defined as Cg1, Cg3,
and IL subregions corresponding to the plates 6-10 according to the atlas of Paxinos and Watson) was dissected from 2-mm-thick
slices, whereas the hippocampus was dissected from the whole brain. The brain specimens were frozen on dry ice and stored at
-80ºC for further analysis.
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Sucrose intake test
After a period of adaptation to laboratory and housing conditions, the animals were trained to consume a palatable sucrose solution
(1%). Training consisted of nine 1 hour-baseline tests in which the sucrose solution was presented to the rats in their home cage
after 14 hours of food and water deprivation. Sucrose intake was measured as differences in bottle weight before and after each test.
Subsequently, sucrose consumption was monitored, under similar conditions, at weekly intervals throughout the whole experiment.
RNA preparation and gene expression analyses
For  gene  expression  analyses,  total  RNA  was  isolated  from  the  different  brain  regions  by  single  step  guanidinium
isothiocyanate/phenol extraction using PureZol RNA isolation reagent (Bio-Rad Laboratories S.r.l.; Segrate, Italy) according to the
manufacturer’s  instructions  and  quantified  by  spectrophotometric  analysis.  The  samples  were  then  processed  for  real-time
polymerase chain reaction (PCR) as previously reported (13) to assess mRNA levels of: Bmal1, Clock, Cry1, Cry2, Per1, Per2, Rev-
Erbα, Rev-Erbβ, Pparα, Nampt and Bhlhe40.
Briefly, an aliquot of each sample was treated with DNase to avoid DNA contamination and subsequently analyzed by TaqMan qRT–
PCR instrument (CFX384 real-time system, Bio-Rad Laboratories S.r.l.) using the iScript one-step RT–PCR kit for probes (Bio-Rad
Laboratories S.r.l.). Samples were run in 384-well format in triplicates as multiplexed reactions with a normalizing internal control
(36B4). Thermal  cycling was initiated with incubation at  50°C for  10 min (RNA retrotranscription),  and then at  95°C for  5 min
(TaqMan polymerase activation). After this initial step, 39 cycles of PCR were performed. Each PCR cycle consisted of heating the
samples at 95°C for 10 s to enable the melting process and then for 30 s at 60°C for the annealing and extension reactions. A
comparative cycle threshold (Ct) method was used to calculate the relative target gene expression. Primer sequences used (Table 1)
were purchased from Eurofins MWG-Operon.
Protein extraction and western blot analysis.
Western blot analysis was used to investigate BMAL1, CLOCK, CRY1, PER1, GR and CREB in the nuclear fraction. Tissues were
manually homogenized using a glass-glass potter in a pH 7.4 cold buffer containing 0.32 M sucrose, 0.1 mM EGTA, 0.1 mM PMSF, 1
mM HEPES solution in presence of  a complete set of  protease (Roche) and phosphatase (Sigma-Aldrich)  inhibitors. The total
homogenate was centrifuged at 2500 rpm for 10 min at 4°C to obtain the pellet corresponding to the nuclear fraction (13) which was
re-suspended in a buffer (20 mM HEPES, 0.1 mM dithiothreitol (DTT), 0.1 mM EGTA) with protease and phosphatase inhibitors.
Total protein content was measured according to the Bradford Protein Assay procedure (Bio-Rad Laboratories), using bovine serum
albumin as calibration standard. Equal amounts of protein were run under reducing conditions on 10% SDS-polyacrylamide gels and
then electrophoretically transferred onto nitrocellulose membranes (Bio-Rad Laboratories). The blots were blocked with 10% nonfat
dry milk and then incubated over night at 4°C with the primary antibodies: BMAL1: 1:5000 (Cell Signaling), CLOCK: 1:5000 (Abcam),
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CRY1: 1:5000 (Thermo Scientific), PER1: 1:5000 (GeneTex), GR 1:500 (Thermo Scientific), and CREB 1:1000 (Cell Signaling).
Membranes were then incubated for 1 h at room temperature with the opportune secondary antibody: BMAL1: 1:2500 (anti-rabbit),
CLOCK: 1:2500 (anti-rabbit), CRY1: 1:2500 (anti-rabbit), PER1: 1:2500 (anti-rabbit), GR 1:2000 (anti-rabbit) and CREB 1:2000 (anti-
rabbit).
Immunocomplexes were visualized by chemiluminescence using the Western Lightning Plus ECL (PerkinElmer) and the Chemidoc
MP imaging system (Bio-Rad Laboratories). Results were normalized using β-actin as an internal standard because its expression is
not regulated by the experimental paradigm used.
Statistical analyses
All the analyses were carried out on individual animals (independent determinations) and analyzed with a two-way ANOVA, with
stress (no stress vs. stress) and treatment (vehicle vs. lurasidone) as independent factors. When appropriate, further differences
were analyzed by Fisher’s Protected Least Significant Difference (PLSD). Sucrose intake after two weeks of CMS was analyzed with
Student’s t test. Significance for all tests was assumed for  P<0.05. For graphic clarity, data are presented as means percent  ±
standard error (SEM) of control group (No Stress/Veh).
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Results
Behavioral characterization of animals exposed to CMS and chronically treated with lurasidone
Sucrose intake was used to establish the behavioral outcome of CMS exposure. As summarized in Table 2, animals were exposed to
2 weeks of CMS develop anhedonia, as indicated by the significant reduction of sucrose intake (-4.5g; p< 0.001 vs Control; Student’s
t test). The pathological phenotype was still present after 7 weeks of CMS (-5g; p< 0.001 vs Control/Vehicle; two-way ANOVA with
Fisher PLSD) and was corrected by a concomitant treatment with lurasidone (+6.1g; p< 0.001 vs Stress/Vehicle; two-way ANOVA
with Fisher PLSD).
Analysis of clock gene expression in the rat prefrontal cortex
Firstly,  we  investigated  the  expression  of  master  clock  genes  in  CMS rats,  as  compared  to  controls,  treated  with  vehicle  or
lurasidone. Specifically we investigated two up-stream regulators,  Bmal1 and Clock, as well as their downstream targets, namely
Cry1, Cry2 and Per1, Per2.
In prefrontal  cortex,  as shown in Figure 1A, there was no main effect  of  stress (F 1,39<0.001,  P>0.05) or  treatment (F1,39=0.139,
P>0.05) on the expression of  Bmal1, although we found a significant stress  x treatment interaction (F1,39=9.843,  P<0.01). Indeed,
chronic lurasidone increased Bmal1 mRNA levels in control rats (+52%, P<0.05 vs No Stress/Veh, Fischer’s PLSD). Conversely, the
enhanced expression of  Bmal1 found in CMS rats (+47%,  P<0.05  vs No Stress/Veh, Fischer’s PLSD) was normalized by drug
exposure (-28%, P=0.062 vs Stress/Veh, Fischer’s PLSD).
When investigating  Clock mRNA levels (Fig. 1B), we found a main effect of treatment (F1,39=14.945,  P<0.001), but not of stress
(F1,39=1.357,  P>0.05)  and  no  significant  stress  x treatment  interaction  (F1,39=0.010,  P>0.05).  Indeed,  lurasidone  administration
increased Clock expression in sham (+38%, P<0.01 vs No Stress/Veh, Fischer’s PLSD) as well as in CMS rats (+40%, P<0.05 vs
Stress/Veh, Fischer’s PLSD). Similarly, Cry1 expression (Fig. 1C) was modulated by lurasidone treatment (F1,39=11.605, P<0.01) but
not  by  CMS  exposure  (F1,39=2.953,  P>0.05),  with  no  stress  x treatment  interaction  (F1,39=0.254,  P>0.05).  Indeed,  lurasidone
significantly up-regulated  Cry1 mRNA levels, independently from the chronic stress (+21%,  P<0.05  vs No Stress/Veh and +33%,
P=0.01 vs Stress/Veh, Fischer’s PLSD). Conversely,  Cry2 expression was modulated by CMS exposure (F1,39= 5.483, P<0.05) as
well as by drug intervention (F1,39=12.665, P=0.001), with no stress x drug interaction (F1,39=1.170, P>0.05) (Fig. 1D). Interestingly,
Cry2 mRNA levels were significantly reduced in CMS rats (-27%,  P<0.05  vs No Stress/Veh, Fischer’s PLSD), an effect that was
normalized by chronic lurasidone administration (+51%, P<0.01 vs Stress/Veh, Fischer’s PLSD).
Per1 mRNA levels (Fig. 1E) were also significantly affected by chronic lurasidone treatment (F 1,39=13.616, P=0.001), which produced
a marked elevation of its expression only in CMS exposed animals (+132%, P=0.001  vs Stress/Veh animals, Fischer’s PLSD).
Lastly,  we found a significant  effect  of  CMS (F1,39=31.662,  P<0.001) and treatment  (F1,39=21.377,  P<0.001)  on  Period 2 (Per2)
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expression (Fig. 1F). CMS significantly reduced its mRNA levels (-47%, P<0.001 vs No Stress/Veh, Fischer’s PLSD), whereas long-
term lurasidone administration was able to normalize these changes (+77%,  P<0.001  vs Stress/Veh, Fischer’s PLSD). Moreover,
drug treatment was able to produce a small but significant elevation of Per2 mRNA levels also in sham animals (+18%, P=0.05 vs
No Stress/Veh, Fischer’s PLSD). Interestingly, comparing the expression of these gene in animals exposed to stress and the
results of the sucrose consumption test, we found a significant positive correlation between the gene expression of Per1
(r=0.5722, P<0.05) (Fig. 2B), Per2 (r=0.5694 P<0.05) (Fig. 2C) and the sucrose preference (Fig. 2), while a negative correlation
was observed for Bma1 (r=-0.4907 P<0.05) (Fig. 2A).
Analysis of Rev-Erbα and Rev-Erbβ mRNA expression in prefrontal cortex
Next, in order to investigate the interlocking feedback loop that regulated the core clock cycle, we analyzed the mRNA levels of Rev-
Erbα and Rev-Erbβ, whose expression is regulated by the heterodimer CLOCK:BMAL1 and that in turn control Bmal1 transcription.
We found that  CMS produced  a slight,  but  significant,  decrease of  Rev-Erbβ mRNA levels  (-15%,  P<0.05  vs No Stress/Veh,
Fischer’s PLSD), an effect that was not present when the animals had received chronic lurasidone (+15%, P<0.05 vs Stress/Veh,
Fischer’s PLSD) (Fig.3B). No significant changes were found for Rev-Erbα expression (Fig.3A).
Analysis of CLOCK:BMAL1 regulated-genes in prefrontal cortex
In order to obtain further  information on potential  changes of  genes downstream from CLOCK:BMAL1 in prefrontal  cortex,  we
investigated the mRNA levels of genes that contain the E-box sequence and whose expression can be regulated by the heterodimer,
including Pparα (Fig. 4A), Nampt (Fig. 4B) and Bhlhe40 (Fig. 4C).
We found a significant effect of stress on Pparα mRNA levels  (Fig. 4A) (F1,38=4.710, P<0.05), which were reduced in CMS rats (-
15%,  P<0.05  vs No Stress/Veh,  Fischer’s  PLSD).  Conversely,  Nampt expression  (Fig.  3B)  was  only  influenced  by  lurasidone
treatment (F1,39=8.128, P<0.01). In particular, Nampt mRNA levels were increased when the drug was administered to CMS animals
(+19%, P<0.01 vs Stress/Veh animals, Fischer’s PLSD). No significant changes in the expression of Bhlhe40 as a consequence of
CMS or lurasidone treatment were found (Fig. 4C).
Analysis of mRNA levels in rat dorsal hippocampus
In the dorsal hippocampus (Table 3), most of the observed changes were driven by chronic exposure to lurasidone. Indeed, we
observed a main effect  of  treatment for  Bmal1,  Clock and  Cry1 (respectively F1,39=27.804,  P<0.001, F1,39=22.017,  P<0.001 and
F1,39=15.562,  P<0.001)  independently  from CMS exposure,  as  indicated  by  the  lack  of  stress  x drug  interaction  (respectively
F1,39=2.013, P>0.05, F1,39=0.701, P>0.05 and F1,39=0.173, P>0.05). Specifically, the expression of all these genes were significantly
up-regulated  by  lurasidone  administration  in  sham  (Bmal1:  +41%,  P<0.001  vs No  Stress/Veh;  Clock:  +33%,  P<0.01  vs No
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Stress/Veh; Cry1: +74%, P<0.01 vs No Stress/Veh, Fischer’s PLSD) as well as in CMS rats (Bmal1: +20%, P=0.01 vs Stress/Veh;
Clock: +46%, P<0.001 vs Stress/Veh; Cry1: +45%, P<0.05 vs Stress/Veh, Fischer’s PLSD). Chronic lurasidone administration had a
significant effect also on period genes (Per1: F1,39=23.352, P<0.001; Per2: F1,39=53.051, P<0.001). Specifically, we found a significant
up-regulation of Per1 and Per2 mRNA levels in sham (respectively: +39%, P<0.001 vs No Stress /Veh; +45%, P<0.001 No Stress
/Veh, Fischer’s PLSD) as well as in CMS rats (respectively: +25%, P<0.01 vs Stress /Veh; +50%, P<0.001 Stress /Veh, Fischer’s
PLSD). Conversely,  Cry2 was the only gene whose expression were influenced by CMS exposure (F1,39=15.187, P<0.001), with a
significant increase of its mRNA levels (+57%, P<0.001 vs No Stress/Veh, Fischer’s PLSD). Rev-Erbα were not modulated by the
CMS (F1,39=0.168,  P>0.05) or by the pharmacological treatment (F1,39=2.585,  P>0.05), while we found a significant effect  of  the
chronic lurasidone administration on Rev-ErbβmRNA levels (F1,39=15.148, P<0.001), whose expression was significantly increased
only in CMS rats treated with lurasidone (+30%, P<0.001 Stress /Veh, Fischer’s PLSD). Nampt expression was also modulated by
drug treatment (F1,39=13.932, P=0.001) without stress x treatment interaction (F1,39=0.091, P>0.05). In fact, we observed a significant
increased of its mRNA levels following lurasidone administration in sham (+27%,  P<0.05  vs Stress /Veh, Fischer’s PLSD) and in
CMS rats (+31%,  P<0.01  vs Stress /Veh, Fischer’s PLSD). No significant changes were found for the expression of  Pparα and
Bhlhe40 in dorsal hippocampus.
Analysis of mRNA levels in rat ventral hippocampus
Limited changes in the expression of clock genes were instead observed in the ventral region of hippocampus (Table 3). Indeed we
found a significant effect  of  stress only on the expression of  Cry2 (F1,37=18.214,  P<0.001). In particular,  its mRNA levels were
increased in CMS rats (+30%, P<0.01 vs No Stress/Veh, Fischer’s PLSD). On the contrary, the expression of Per1 was modulated
by the drug treatment (F1,39=44.099,  P=0.001) but not by CMS exposure (F1,39=0.931,  P>0.05). Indeed,  Per1 mRNA levels were
markedly up-regulated following lurasidone treatment in both sham and CMS rats (respectively +87%, P<0.001 vs No Stress/Veh
and +97%, P<0.001 vs Stress/Veh, Fischer’s PLSD). Lastly, lurasidone was also able to modulate the expression of Per2 selectively
in CMS rats,  as indicated by the significant stress  x treatment interaction (F1,39=10.263,  P<0.01).  Indeed, CMS rats  chronically
treated with lurasidone had higher levels of Per2 (+45%, P<0.01 vs Stress/Veh, Fischer’s PLSD) as compared to CMS rats treated
with vehicle. We didn’t find any significant effect on the expression of the other genes investigated in ventral hippocampus
Analysis of clock genes protein levels in rat prefrontal cortex
Considering  that  the  prefrontal  cortex  was  the  brain  region  where major  changes  were  evident  following CMS exposure and
lurasidone treatment, we decided to establish if  transcriptional changes were associated to similar modifications at translational
levels. Hence, we investigated the protein levels of BMAL1, CLOCK, CRY1 and PER1 in the nuclear fraction of the prefrontal cortex
(prototypical western blot analyses of these protein are shown in Figure 5).
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As shown in Figure 6, we found a main effect of stress on BMAL1 (F1,24=3.663, P=0.05) (Fig. 5A) and CLOCK (F1,24=6.956, P<0.05)
(Fig. 6B) protein levels, with a significant reduction in CMS rats (BMAL1: -33%, P<0.05 vs No Stress/Veh, Fischer’s PLSD; CLOCK:
-36%, P<0.05 vs No Stress/Veh, Fischer’s PLSD). Chronic lurasidone treatment was able to normalize the changes of BMAL1 levels
(+40%, P>0.05 vs Stress/Veh, Fischer’s PLSD), without affecting the reduction of CLOCK levels produced by CMS exposure.
A significant effect of the CMS was also found for CRY1 levels (Fig. 6C) (F1,24=6.526,  P<0.05), with a significant stress X drug
interaction  (F1,24=23.997,  P<0.001).  Indeed,  CRY1 protein  levels  were  markedly  reduced  in  CMS rats  (-47%,  P<0.001  vs No
Stress/Veh, Fischer’s PLSD), an effect that was completely normalized by chronic lurasidone administration (+70%,  P<0.001  vs
Stress/Veh,  Fischer’s  PLSD).  Interestingly,  lurasidone  administration  to  sham  rats  significantly  decreased  CRY1 levels  (-25%,
P<0.05 vs No Stress/Veh animals, Fischer’s PLSD). Conversely, while PER1 protein levels (Fig. 6D) were also significantly reduced
in CMS rats (-40%, P<0.05 vs No Stress/Veh animals, Fischer’s PLSD), these changes were not affected by chronic drug treatment.
Analysis of Per1 transcription regulators in rat prefrontal cortex
In addition to the CLOCK:BMAL1 E-box, the Period1 gene promoter contains the glucocorticoid-responsive element (GRE) and the
cAMP-responsive element (CRE), suggesting that other signaling pathways may control its expression (Fig. 7A). Hence, in order to
establish the involvement of such systems on Per1 gene expression changes, we investigated the protein levels of glucocorticoid
receptors (GR) and of  the transcription factor CREB in the nuclear extract  from the prefrontal  cortex (prototypical  western blot
analyses of these protein are shown in Figure 5).
We found a significant stress x treatment interaction (F1,24=13.073, P<0.01) for GR levels (Fig. 7B). Indeed, in agreement with the
modifications observed for Per1 expression (Fig. 1E), GR levels were significantly reduced following CMS exposure (-31%, P<0.01
vs No Stress/Veh, Fischer’s PLSD), an effect that was normalized by lurasidone treatment (+41%, P<0.01 vs Stress/Veh, Fischer’s
PLSD). It is interesting to notice that GR levels were reduced in sham rats that were chronically treated with lurasidone (-20%,
P<0.05  vs No Stress/Veh, Fischer’s PLSD). On the contrary, we found a significant stress  x drug interaction on CREB protein
(F1,23=7.053, P<0.05) (Fig. 7C). The levels of this transcription factor were indeed significantly up-regulated by lurasidone treatment,
but only in sham rats (+103%, P<0.05 vs No Stress/Veh animals, Fischer’s PLSD).
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Discussion 
In this study, we provide evidence that animals exposed to chronic stress show alterations of the clock gene machinery, which is
essential for maintaining the circadian rhythms. The changes produced by CMS, which produces a depressive-like phenotype, are
suggestive of altered transcription and translation of clock genes primarily in the prefrontal cortex. Interestingly, we demonstrate that
chronic treatment with the multi receptor drug lurasidone is able to normalize some of these alterations (Fig. 8).
While  the circadian  clock  has  been  investigated in  many non-brain  tissues,  such  as  the liver,  where it  plays  a  major  role in
metabolism, less is known about the alterations of this system, outside the SCN, within key brain regions, which play an important
role  in  different  neuropsychiatric  conditions.  Furthermore,  to  our  knowledge,  no  studies  have  investigated  the  influence  of  a
pharmacological intervention on these mechanisms under a “pathological situation”, as represented by the CMS paradigm. Our
results showed that clock gene expression is modulated by stress exposure primarily in the prefrontal cortex and that most of these
changes can  be normalized by  chronic  lurasidone treatment,  which  is  also able  to  regulate  the clock  gene machinery in  the
hippocampus.
Under physiological conditions, the heterodimer CLOCK:BMAL1 drives clock-controlled gene (CCG) expression of both core and
interlocked feedback loop genes. Even if, being a cycle it is difficult to establish a temporal consecution of the changes observed, in
the prefrontal cortex, the reduction of BMAL1 and CLOCK protein levels in the nuclear compartment after CMS exposure may be
responsible for the reduced expression of Rev-Erbβ, Cry2, Per1 and Per2. Interestingly, since REV-ERBs bind the RRE present in
the promoter of  Bmal1 and repress its expression  (6), the low levels of  Rev-Erbβ transcripts could lead to a dysfunction of the
interlocked feedback loop and, in turn, to a decrease of its repressive activity on  Bmal1 gene, which indeed was up-regulated in
CMS rats. As mentioned before, also the reduction of Cry2, Per1 and Per2 mRNA levels following chronic stress exposure may be a
consequence of the decreased CLOCK:BMAL1 activity, an alteration that was paralleled by a significant reduction of CRY1 and
PER1 protein levels in the nucleus. Furthermore, the dysregulation of  mTor pathways that is observed in CMS rats  (12) may also
contribute to the modulation of Per1/2 gene expression (14). 
One potential link between stress exposure and the dysfunction in clock gene machinery is represented by changes of HPA axis
function. First, plasma concentration of corticosterone displays a time-dependent variation either in diurnal and nocturnal animals
(15), a phenomenon that is controlled by both the master clock in the SCN and the peripheral clock within the adrenal gland (16, 17).
The activity of this hormone is mediated by glucocorticoid receptors (GRs) that, after binding to their endogenous ligand, enter the
nucleus, interact with specific DNA responsive elements (GRE), leading to transcriptional regulation of different genes. We showed
that GR protein levels were significantly reduced in the nuclear fraction of the prefrontal cortex from CMS rats, an effect that was
normalized by lurasidone treatment. Since a canonical GRE is present in the promoter region of the Per1 gene, while an intronic GR-
binding sequence confers  GC responsiveness  to  Per2 (18),  the effects  observed on GR protein  levels  may contribute  to  the
alterations found in  Per’s mRNA levels. Accordingly, it has been recently shown that the expression of  Per2 is also mediated by
12
BMAL1-dependent binding of GR to the overlapping GRE/E-box in the upstream region of the Per2 gene (19). Moreover, since the
binding of CRY1/2 with GR alters the transcriptional response to glucocorticoids (20), the reduction of CRY1 protein levels combined
with GR impairment found in our model may affect the expression of a wide variety of genes, extending the mechanisms potentially
affected by chronic stress exposure. 
Interestingly, it has been demonstrated that an acute restraint stress causes a rapid increase in the level of Period 1 mRNA (21), in
line with the idea that, while prolonged stress has negative outcomes and may lead to the development of pathological phenotypes,
brief stressors may produce an activation of protective mechanisms that may help the organism in coping with the adverse condition.
Furthermore, it has been demonstrated that 7 days of stress did not influence the protein levels of PER2 in hippocampus and in the
prefrontal cortex, while decreased it in the SCN (22). As mentioned before most studies have focused on the SCN, where it has been
shown that 4 weeks of chronic unpredictable stress reduced the amplitude of  Per2, but not  Per1, oscillations, an effect that was
normalized by desipramine treatment (23). 
Only recently the effect of prolonged stress exposure on the expression of clock genes was analyzed in brain regions such as the
hippocampus, the amygdala and the nucleus accumbens. Indeed, it has been shown that CLOCK protein levels were modulated in
the hippocampus, but not in the SCN, of stressed rats (24). Moreover, a disturbed diurnal oscillation of the expression of Clock, Cry2,
Per1, Per3, Id2, Rev-erbα, Ror-β, Ror-γ was observed in the mouse amygdala (25), and alteration of Per1, Per2, Clock and Bmal1
rhythms were also reported in the nucleus accumbens (7).
One interesting finding of our study is the ability of chronic treatment with lurasidone, a multi-receptor modulator, with the highest
affinity for 5-HT7 receptors, followed by D2, 5-HT2A and 5-HT1A receptors, to regulate clock gene expression under CMS as well as in
normal rats, an effect that, as previously demonstrated (12), was paralleled by antidepressant effect at behavioral levels. With this
study, we demonstrated that chronic lurasidone administration was able to normalize the reduction of the protein levels of BMAL1,
but  not  of  CLOCK, in  the nuclear  compartment  of  CMS rats.  Given that  the mRNA levels  of  all  the genes  controlled by  the
heterodimer CLOCK:BMAL1 were restored after the pharmacological treatment, we infer that the effects on BMAL1 may be sufficient
to  restore the basal  transcriptional  levels  of  Rev-Erbβ,  Crys and  Pers. However,  as  described above,  it  is  feasible that  other
pathways may contribute to the observed effects, since we have also demonstrated that GR protein levels were modulated by
lurasidone administration to CMS rats.
In the ventral hippocampus, which participates in emotional regulation and anxiety-related behaviors, we found limited effects of
stress exposure as well as of lurasidone administration. Conversely, in the dorsal part of the hippocampus, which is preferentially
involved in learning and memory, we found major effects of the pharmacological treatment that significantly increased the expression
of Bmal1, Clock, Cry1, Per1 and Per2, independently from the stress exposure. These results are in agreement with data from Uz
and  colleagues  showing  that  chronic  fluoxetine  treatment  produced  a  significant  increase  of  Clock,  Bmal1,  Per2,  Cry2 gene
expression in the hippocampus of normal rats (26). Moreover, the results of the present study demonstrate that, while lurasidone has
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some modulatory activity in normal animals, as previously demonstrated (27-30), its effects are more pronounced in CMS rats than
in normal rats, suggesting a greater effectiveness of the pharmacological treatment under pathological conditions.  Since lurasidone
is characterized by multi receptor profile, it is difficult to establish which mechanism may contribute to its modulatory activity on clock
gene in sham as well as in stressed rats. One feasible candidate is represented by 5-HT7 receptors, towards which the drug has the
highest affinity. Indeed, it has been reported that the 5-HT7 receptors are implicated in the circadian rhythms phase resetting and
also in  the REM sleep in  human as  well  as  in  rodents  (31,  32).  Moreover,  the activity  of  lurasidone in  prefrontal  cortex and
hippocampus is consistent with the modulatory activity of  GABA – glutamate function through the blockade of 5-HT7 receptors
located on GABAergic interneurons (33). 
In order to investigate possible changes downstream from the clock gene machinery, we have also investigated the expression of
genes  that,  containing  the  E-box,  are  controlled  by  the  CLOCK:BMAL1  heterodimer,  even  if  they  do  not  belong  to  the
aforementioned loops. In particular, we found that the expression of  Pparα was specifically decreased in the prefrontal cortex of
stressed animals, while  Nampt transcription was significantly increased after lurasidone treatment in prefrontal cortex and in the
dorsal hippocampus.
The role of  Pparα  has not been extensively investigated, but it may be involved in the control of the food intake and in
metabolic processes (34). Since one of the most profound effects of stress exposure is weight loss, often due to a reduction of food
intake, it  may be inferred that the reduction of  Pparαexpression in CMS rats may, at  least in part,  contribute to dysmetabolic
changes brought about by stress exposure. Since it  has been demonstrated that Nampt plays a fundamental  role in neuronal
survival and in cognitive function (35), the increase of Nampt expression after lurasidone treatment may contribute to the protective
and procognitive effects of this multi receptor antipsychotic drug (10, 11).
There are two major limitations in the present study. First, we performed our analyses at a single time point, which does not allow us
to assess a potential shift of the peak expression in these genes or a loss of rhythmicity. Nevertheless we believe we are providing
compelling evidence that clock gene expression are dys-regulated as a consequence of CMS exposure and/or pharmacological
intervention, and that such changes do occur in brain regions outside the SCN. Second, while CMS rats show a clear anhedonic
phenotype, we do not have any information about possible alterations of biological rhythms (i.e. analysis of activities or of sleep).
However, although further studies are needed to clarify these issues, for the first time, our study provides a clear indication that a
pharmacological treatment is able to modulate clock gene expression in an animal model of depressive disorder within brain regions
different from the SCN. We think that the changes observed in the prefrontal cortex that play a fundamental role in the onset and
development of  psychiatric  diseases may help to clarify the link between disruption of  circadian rhythms and these pathologic
conditions.
To  conclude,  the  alterations  in  clock  genes  expression  due  to  CMS exposure  may  underline  the  development  of  symptoms
correlated with circadian abnormalities. Moreover, the ability of chronic lurasidone treatment to modulate clock genes expression
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together with the normalization of the anhedonic phenotype suggest a potential role of this drug in ameliorating the disruption of
circadian rhythms observed in subject affected by major depression and stress-related disorders (11, 12, 27, 28, 36, 37).
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Figure legends
Figure  1:  Analysis  of  clock  genes  expression  in  the  prefrontal  cortex  of  rats  exposed  to  CMS:  effect  of  lurasidone
treatment. The mRNA levels of  Bmal1 (A),  Clock (B),  Cry1 (C),  Cry2 (D),  Per1 (E) and Per2 (F) were measured in the prefrontal
cortex of non-stressed or chronically stressed rats, treated for 5 weeks with vehicle or lurasidone and killed 24 h after the last
administration.  The data,  expressed as  a  percentage of  No Stress/Vehicle  (set  at  100%),  are  the mean ± SEM of  at  least  9
independent determinations. *p<0.05, ** p<0.01, ***p<0.001 vs. No Stress/Vehicle; # p<0.05, ## p<0.01, ###p<0.001 vs. Stress/Vehicle
(two-way ANOVA with PLSD).
Figure 2: Correlation analyses between Bmal1 (A), Per1 (B), Per2 (C) and sucrose preference in the prefrontal cortex of rats
exposed to stress. Analyses by Pearson’s product–moment correlation (r). The data derived from 19 independent determinations.
Figure 3: Analysis of Rev-Erbα, Rev-Erbβ expression in the prefrontal cortex of rats exposed to CMS: effect of lurasidone
treatment. The mRNA levels of Rev-Erbα (A), Rev-Erbβ (B) were measured in the prefrontal cortex of non-stressed or chronically
stressed rats, treated for 5 weeks with vehicle or lurasidone and killed 24 h after the last administration. The data, expressed as a
percentage of No Stress/Vehicle (set at 100%), are the mean ± SEM of at least 9 independent determinations. *p<0.05 vs. No
Stress/Vehicle; # p<0.05 vs. Stress/Vehicle (two-way ANOVA with PLSD).
Figure 4: Analysis of CLOCK:BMAL1 heterodimer regulated-genes expression in the prefrontal cortex of rats exposed to
CMS: effect of lurasidone treatment. The mRNA levels of Pparα (A), Nampt (B) and Bhlhe40 (C) were measured in the prefrontal
cortex of non-stressed or chronically stressed rats, treated for 5 weeks with vehicle or lurasidone and killed 24 h after the last
administration.  The data,  expressed as  a  percentage of  No Stress/Vehicle  (set  at  100%),  are  the mean ± SEM of  at  least  9
independent determinations. *p<0.05 vs. No Stress/Vehicle; ## p<0.01 vs. Stress/Vehicle (two-way ANOVA with PLSD).
Figure 5: Representative western blot analyses of the BMAL1, CLOCK, CRY1, PER1, GR, CREB and  b-. Experimental
conditions are described in Materials and methods.
Figure 6: Analysis of BMAL1, CLOCK, CRY1 and PER1 protein levels in the prefrontal cortex of rats exposed to CMS: effect
of lurasidone treatment. The protein levels of BMAL1 (A), CLOCK (B), CRY1 (C) and PER1 (D) were measured in the nucleus of
prefrontal cortex of non-stressed or chronically stressed rats, treated for 5 weeks with vehicle or lurasidone and killed 24 h after the
last administration. The data, expressed as a percentage of No Stress/Vehicle (set at 100%), are the mean ± SEM of at least 6
independent determinations. *p<0.05, ***p<0.001 vs. No Stress/Vehicle; ###p<0.001 vs. Stress/Vehicle (two-way ANOVA with PLSD).
Figure 7: Analysis of GR and CREB protein levels in the prefrontal cortex of rats exposed to CMS: effect of lurasidone
treatment. The protein levels  of  GR (B) and CREB (C) were measured in the nucleus of  prefrontal  cortex of  non-stressed or
chronically stressed rats, treated for 5 weeks with vehicle or lurasidone and killed 24 h after the last administration. (A) Schematic
representation of the Per1 promoter. The data, expressed as a percentage of No Stress/Vehicle (set at 100%), are the mean ± SEM
of at least 6 independent determinations. *p<0.05, **p<0.01 vs. No Stress/Vehicle; # p<0.05 vs. Stress/Vehicle (two-way ANOVA with
PLSD).
Figure 8: Schematic representation of the effect of CMS and lurasidone treatment on the clock genes expression.
CMS exposure modulated transcription and translation of clock genes primarily in the prefrontal cortex, and chronic treatment with
antipsychotic lurasidone is able to normalize some of these alterations. Indeed, compare to the basal condition (Panel A), stress
exposure (Panel B) reduced the protein levels of BMAL1, CLOCK and GR in the nuclear compartments producing a decrease in the
expression of the Rev-Erbs, Pers and Crys genes. In turn the reduction of  Rev-Erbband of  Hdac mRNA levels may underlie the
decreased transcription of Bmal1. Moreover, the effect on Pers and Crys gene was paralleled by a similar alteration of the protein
levels. On the other side, chronic treatment with lurasidone (Panel C) was able to restore the normal protein levels BMAL1 and GR
with consequent normalization of the expression of the target genes. Moreover, here, the expression of Bmal1 was similar to those
observed  in  basal  condition  (Panel  A)  probably  because  also  Rev-Erb±and  of  Hdac mRNA levels  were  normalized  by  the
pharmacological treatment. Finally, lurasidone was able to correct only the alteration due to the CMS of CRY1.
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Table 1 Sequences of Forward and Reverse Primers and Probe used in Real-time PCR Analyses 
Gene Forward primer Reverse primer Probe
Bmal1 ATCCTGAGCACGGTGAGTTT AAGAGGCGTCGGGACAAAAT CAACATGCAATGCGATGTCC
Clock ATCTTTGTCGGCGTTGAGGA AAAGGTTCGATCACAGCCCA CAGAAGCTCAAGAAAGTCCTCG
Cry1 TCAATCCACGGAAAGCCTGT CCACAAACAACCCACGCTTT GGAACCCCATCTGTGTTCAA
Cry2 TAGTCCACGCCAATGATGCA TGCCCAAACTGAAAGGCTTC TCTATGAGCCCTGGAATGCT
Per1 AGAGCTGAGTCCTTGCCATT TGGCTGATGACACTGATGCA AGCGGAGTTCTCACAGTTCA
Per2 TTGTGCCTCCCGATGATGAA AGTGGGCAGCCTTTCGATTA GTACATCACACTGGACACTAGC
Rev-Erbα ACGTCCCCACACACTTTACA ACAAGTGGCCATGGAAGACA GGCACCAGCAACATTACCAA
Rev-Erbβ ACGGATGAGTGTTTCCTGCA AGCGACGAGGAAATGAGCTT TTCTGGTGTCTGCAGATCGA
Pparα TGCATTGTGTGACATCCCGA TGGCGTACGACAAGTGTGAT GAACCGGAACAAATGCCAGT
NAMPT GGACGGAGTGGATATCAATAC GAGGTCTCTGGTTAACTTCTG AATGTCTCCTTTGGTTCTGG
BHLHE40 GGACGGAGTGGATATCAATAC GAGGTCTCTGGTTAACTTCTG AATGTCTCCTTTGGTTCTGG
36B4 TCAGTGCCTCACTCCATCAT AGGAAGGCCTTGACCTTTTC TGGATACAAAAGGGTCCTGG
 
Table 2 Effect of CMS and Lurasidone treatment on Sucrose intake 
 
Experimental groups Baseline Week 2 Experimental groups Week 7 
No stress 11.6 ± 0.9 11.2 ± 0.5 No stress/Vehicle 11.0 ± 0.8 
   No stress/Lurasidone 12.7 ± 0.9 
Stress 11.8 ± 0.4 6.7 ± 0.5*** Stress/Vehicle 6.0 ± 0.9°°° 
   Stress/Lurasidone 12.1 ± 0.9### 
2 weeks of CMS induced a significant reduction of the sucrose consumption, effect that was already 
present after 7 weeks of stress, but was normalized by 5 weeks of concomitant treatment with 
lurasidone. The data, expressed as grams (g) of sucrose intake, are the mean ± SEM of at least 9 
independent determinations. ***p<0.001 vs No stress (Student’s t test); °°°p<0.001 vs No 




Table 3:  Analysis of clock and CCGs genes expression in the hippocampus of rats exposed to CMS: effect of lurasidone
treatment 
No Stress/Vehicle No Stress/Lurasidone Stress/Vehicle Stress/Lurasidone
Dorsal Hippocampus
Bmal1 1.008 1.420*** 1.191 1.428##
Clock 1.009 1.343** 1.026 1.506###
Cry1 1.047 1.826** 1.381 2.011#
Cry2 1.050 1.229 1.648*** 1.482
Per1 1.022 1.417*** 1.217 1.519##
Per2 1.013 1.467*** 1.139 1.698###
Rev-Erbα 1.013 1.112 1.031 1.150
Rev-Erbβ 1.010 1.126 1.055 1.364###
Pparα 1.013 1.064 1.016 1.033
Nampt 1.027 1.303* 1.012 1.337##
Bhlhe40 1.037 1.089 1.153 1.156
Ventral Hippocampus
Bmal1 1.062 1.146 1.085 1.181
Clock 0.956 0.909 1.038 0.990
Cry1 1.016 1.126 1.151 1.145
Cry2 0.945 0.968 1.228** 1.283###
Per1 1.018 1.905*** 1.079 2.124##
Per2 1.026 0.891 0.849 1.229
Rev-Erbα 1.022 1.028 0.886 0.967
Rev-Erbβ 1.016 1.071 1.116 1.158
Pparα 1.011 1.029 0.968 0.977
Nampt 1.015 1.171 1.089 1.297
Bhlhe40 1.020 1.000 1.058 1.085
The mRNA levels of Bmal1, Clock, Cry1, Cry2, Per1, Per2, Rev-Erbα, Rev-Erbβ, Pparα, NAMPT and BHLHE40 were measured in
the dorsal and ventral hippocampus of non-stressed or chronically stressed rats, treated for 5 weeks with vehicle or lurasidone and
killed 24 h after  the last  administration. The data,  expressed  as fold change, are the mean ± SEM of at  least 9 independent
determinations. ** p<0.01, ***p<0.001 vs. No Stress/Vehicle; # p<0.05, ## p<0.01, ###p<0.001 vs. Stress/Vehicle (two-way ANOVA with
SCPHT). 








